BCOR mutations are detected in approximately 4% of adult de novo AML, 8% of secondary AML, and 1.7% of paediatric AML cases27–29 and cause shorter transformation-free survival in MDS30. This evidence concerns the gene BCOR and acute myeloid leukemia.